New formulation helps RNA vaccines withstand high temperatures

AI Summary

MIT researchers have developed a formulation intended to help RNA vaccines remain stable at higher temperatures, potentially reducing their reliance on ultracold storage. The approach could support development and distribution of vaccines for diseases including COVID-19 and cancer.

RNA vaccines, which have proved effective against COVID-19, are now being developed for many other diseases, including cancer. One drawback is that they require ultracold storage, but MIT researchers have found a promising way to overcome that limitation.